Published in J Clin Oncol on April 29, 2009
The Women In Steady Exercise Research (WISER) Survivor Trial | NCT01515124
Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer | NCT03017560
Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol (2011) 4.07
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer (2015) 2.63
Epigenetic regulation of SOX9 by the NF-κB signaling pathway in pancreatic cancer stem cells. Stem Cells (2013) 2.40
Predictors of falls among community-dwelling older adults with cancer: results from the health and retirement study. Support Care Cancer (2014) 2.26
Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys (2012) 2.17
Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst (2010) 2.04
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst (2014) 1.96
Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg (2014) 1.86
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol (2011) 1.76
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood (2015) 1.49
Use of geriatric assessment for older adults in the oncology setting: a systematic review. J Natl Cancer Inst (2012) 1.42
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. J Clin Oncol (2014) 1.39
Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol (2012) 1.39
Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol (2013) 1.32
Cancer survivors in the United States: a review of the literature and a call to action. Int J Med Sci (2012) 1.30
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol (2015) 1.25
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Development and evaluation of a decision aid on mammography screening for women 75 years and older. JAMA Intern Med (2014) 1.18
Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. Clin Interv Aging (2014) 1.17
Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice. Br J Cancer (2013) 1.15
Correlation of long non-coding RNA expression with metastasis, drug resistance and clinical outcome in cancer. Oncotarget (2014) 1.13
Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer. Cell Stem Cell (2015) 1.11
Gastrointestinal malignancy and the microbiome. Gastroenterology (2014) 1.07
Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities. Lung Cancer (2013) 1.07
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst (2012) 1.07
Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett (2012) 1.06
Does enrollment in cancer trials improve survival? J Am Coll Surg (2013) 1.06
Age and cancer risk: a potentially modifiable relationship. Am J Prev Med (2014) 1.04
Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol (2014) 1.04
Cancer prevention for the next generation. J Adolesc Health (2013) 1.04
Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit. World J Urol (2015) 1.04
Engaging diverse populations about biospecimen donation for cancer research. J Community Genet (2014) 1.02
Unplanned presentations of cancer outpatients: a retrospective cohort study. Support Care Cancer (2012) 1.01
Research priorities in geriatric oncology: addressing the needs of an aging population. J Natl Compr Canc Netw (2012) 1.01
Providing cancer care to a graying and diverse cancer population in the 21st century: are we prepared? J Clin Oncol (2009) 1.00
Potential chemopreventive agents based on the structure of the lead compound 2-bromo-1-hydroxyphenazine, isolated from Streptomyces species, strain CNS284. J Med Chem (2010) 0.99
Differences in the symptom experience of older versus younger oncology outpatients: a cross-sectional study. BMC Cancer (2013) 0.98
Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica (2012) 0.98
Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review. Ann Oncol (2013) 0.97
Double Jeopardy? Age, Race, and HRQOL in Older Adults with Cancer. J Cancer Epidemiol (2012) 0.97
A systematic review of unmet needs of newly diagnosed older cancer patients undergoing active cancer treatment. Support Care Cancer (2012) 0.96
Effective recruitment strategies and community-based participatory research: community networks program centers' recruitment in cancer prevention studies. Cancer Epidemiol Biomarkers Prev (2014) 0.96
Characteristics of older newly diagnosed cancer patients refusing cancer treatments. Support Care Cancer (2010) 0.96
Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood (2016) 0.96
Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol (2014) 0.95
Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. Oncotarget (2015) 0.95
Geriatric assessment is associated with completion of chemotherapy, toxicity, and survival in older adults with cancer. J Geriatr Oncol (2013) 0.94
Effectiveness of radiation for prevention of mastectomy in older breast cancer patients treated with conservative surgery. Cancer (2012) 0.94
Apigenin and naringenin suppress colon carcinogenesis through the aberrant crypt stage in azoxymethane-treated rats. Exp Biol Med (Maywood) (2010) 0.94
Disparities in perceived unmet need for supportive services among patients with lung cancer in the Cancer Care Outcomes Research and Surveillance Consortium. Cancer (2014) 0.93
Compliance to therapy-elderly head and neck carcinoma patients. Can Geriatr J (2014) 0.93
Out-of-pocket expenses and treatment choice for men with prostate cancer. Urology (2012) 0.92
Identifying key questions to advance research and practice in cancer survivorship follow-up care: a report from the ASPO Survivorship Interest Group. Cancer Epidemiol Biomarkers Prev (2009) 0.92
Opportunities for cancer prevention during midlife: highlights from a meeting of experts. Am J Prev Med (2014) 0.92
Breast cancer experience and survivorship among Asian Americans: a systematic review. J Cancer Surviv (2013) 0.92
The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology. J Oncol Pract (2016) 0.91
Unmet supportive care needs in colorectal cancer: differences by age. Support Care Cancer (2011) 0.91
Quality of life changes during the pre- to postdiagnosis period and treatment-related recovery time in older women with breast cancer. Cancer (2014) 0.91
Caregiving Choice and Emotional Stress Among Cancer Caregivers. West J Nurs Res (2013) 0.91
Urinary calculi and risk of cancer: a nationwide population-based study. Medicine (Baltimore) (2014) 0.90
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol (2014) 0.90
Treatment of older patients with head and neck cancer: a review. Oncologist (2013) 0.89
The Minority Training Program in Cancer Control Research: impact and outcome over 12 years. J Cancer Educ (2012) 0.89
Epigenetics modifications and therapeutic prospects in human thyroid cancer. Front Endocrinol (Lausanne) (2012) 0.89
The fall rate of older community-dwelling cancer patients. Support Care Cancer (2012) 0.88
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol (2016) 0.88
Systematic review of falls in older adults with cancer. J Geriatr Oncol (2014) 0.88
Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer. Breast Cancer Res Treat (2011) 0.88
Information and communication needs of Chinese American breast cancer patients: perspectives on survivorship care planning. J Community Support Oncol (2014) 0.88
Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin. Bone Marrow Res (2013) 0.88
Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell (2013) 0.88
Highlights from a workshop on opportunities for cancer prevention during preadolescence and adolescence. J Adolesc Health (2013) 0.88
A pilot study of a culturally targeted video intervention to increase participation of African American patients in cancer clinical trials. Oncologist (2012) 0.87
Geriatric oncology research to improve clinical care. Nat Rev Clin Oncol (2012) 0.87
The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer. J Geriatr Oncol (2015) 0.87
Patterns of care in older patients with squamous cell carcinoma of the head and neck: a surveillance, epidemiology, and end results-medicare analysis. J Geriatr Oncol (2013) 0.87
Aging, Clonality, and Rejuvenation of Hematopoietic Stem Cells. Trends Mol Med (2016) 0.86
Planning for the future: cancer incidence projections in Switzerland up to 2019. BMC Public Health (2014) 0.86
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic. J Natl Compr Canc Netw (2014) 0.86
Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030. J Clin Oncol (2016) 0.85
Primary care perspectives on prostate cancer survivorship: implications for improving quality of care. Urol Oncol (2011) 0.85
Estrogen Receptor Status and the Future Burden of Invasive and In Situ Breast Cancers in the United States. J Natl Cancer Inst (2015) 0.85
Quality of life during the course of cancer treatment in older newly diagnosed patients. Results of a prospective pilot study. Ann Oncol (2010) 0.85
Cardiovascular complications of breast cancer therapy in older adults. Oncologist (2011) 0.85
Adjuvant systemic therapy in older women with breast cancer. Breast Cancer (Dove Med Press) (2016) 0.85
Prevalence and Predictors of Burnout Among Hospice and Palliative Care Clinicians in the U.S. J Pain Symptom Manage (2015) 0.84
Infective endocarditis and cancer in the elderly. Eur J Epidemiol (2015) 0.84
Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Neoplasia (2014) 0.84
Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer Prev Res (Phila) (2013) 0.84
Collaboration Between Surgeons and Medical Oncologists and Outcomes for Patients With Stage III Colon Cancer. J Oncol Pract (2015) 0.84
Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist (2015) 0.84
The future workforce in cancer prevention: advancing discovery, research, and technology. J Cancer Educ (2012) 0.83
Functional outcomes by age for inpatient cancer rehabilitation: a retrospective chart review. J Appl Gerontol (2012) 0.83
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A (2007) 4.97
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Breast carcinoma in men: a population-based study. Cancer (2004) 4.88
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol (2002) 4.18
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys (2009) 3.91
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Trastuzumab in the treatment of breast cancer. N Engl J Med (2005) 3.86
Bone imaging in metastatic breast cancer. J Clin Oncol (2004) 3.85
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol (2007) 3.75
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol (2007) 3.46
Male breast cancer. Lancet (2006) 3.41
Breast cancer in men. Ann Intern Med (2002) 3.39
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA (2013) 3.38
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol (2008) 3.09
Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol (2006) 3.08
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst (2005) 2.93
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Race, quality of care, and outcomes of elderly patients hospitalized with heart failure. JAMA (2003) 2.77
Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst (2011) 2.77
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
Is breast cancer survival improving? Cancer (2004) 2.73
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst (2006) 2.69
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol (2009) 2.64
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol (2011) 2.43
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States. J Clin Oncol (2014) 2.42
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008) 2.42
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol (2005) 2.39
Use of radiation therapy in the last 30 days of life among a large population-based cohort of elderly patients in the United States. J Clin Oncol (2012) 2.38
Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol (2006) 2.32
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
Positive surgical margins and ipsilateral breast tumor recurrence predict disease-specific survival after breast-conserving therapy. Cancer (2003) 2.29
Variability of target and normal structure delineation for breast cancer radiotherapy: an RTOG Multi-Institutional and Multiobserver Study. Int J Radiat Oncol Biol Phys (2009) 2.27
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat (2003) 2.26
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22